Learn About PROVENGE

PROVENGE Is a Significant Advance in the Treatment of Metastatic CRPC

PROVENGE is the first and only FDA-approved personalized immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC). By culturing a patient’s own immune cells with a prostate-specific antigen, PROVENGE is designed to activate the power of the immune system to fight advanced prostate cancer.

Learn More About PROVENGE

Watch the Video: Learn about the PROVENGE mechanism of action
Understand the Efficacy: PROVENGE extends median survival in men with asymptomatic or minimally symptomatic CRPC
Analyze Safety: Understand how PROVENGE provides a side effect profile you can manage
Examine the Trial Design: Find out more about the Phase 3 IMPACT Trial
Identify Patients for PROVENGE: Learn about the straightforward patient selection
Learn About Administration: PROVENGE therapy can be completed in about one month
Become a Provider: Learn how to become a PROVENGE provider
Explore Comprehensive Support Services: Dedicated case managers provide support throughout therapy, including reimbursement and patient support

Next: Mechanism of Action

References

Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
Data on file. Dendreon Corporation.
PROVENGE [package insert]. Dendreon Corporation; June 2011.
NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.4.2011. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed October 24, 2011.

INDICATION

PROVENGE^® (sipuleucel-T) is approved by the FDA as an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Dendreon supports all prostate cancer advocates in their efforts to help raise awareness of prostate cancer and improve the lives of those living with prostate cancer. Please click on the organizations displayed to find out what they are doing in support of Prostate Cancer Awareness, including possible events in your community. And, you can show your support for Prostate Cancer Awareness by clicking on the badges to the right to post to your personal site, Twitter page (use 112px x 112px), or Facebook page (use 230px x 65px).